Non-Medical Switching: A Lose-Lose Scenario? Lessons for Biosimilar Players
Non-medical switching (NMS) seems attractive on paper but often leads to poor clinical outcomes and higher overall costs to the payer. As biosimilars begin to enter the US market, what can manufacturers learn from previous attempts to change a patient’s medication?
Idrisa Mshelia, Senior Associate; Dr. Priya Kar, Director; and Dr. Luke Solon, Vice President
With increasing healthcare costs, including the high price of specialty drugs, non-medical switching (NMS) seems like an intuitive idea for US payers to reduce costs
NMS can negatively affect patient outcomes, including causing new side effects
NMS will have critical implications for manufacturers in terms of the upcoming biosimilars of drugs with a significant budget impact on the healthcare system
- Non-Medical Switching: Impact on Movement Disorders Patients’ Access and Care. International Parkinson and Movement Disorder Society. https://www.mdsabstracts.org/abstract/non-medical-switching-impact-on-movement-disorders-patients-access-and-care/ (September 2019).
- A Study of the Qualitative Impact of Non-Medical Switching. Alliance for Patient Access (AfPA). https://admin.allianceforpatientaccess.org/wp-content/uploads/2020/02/AfPA_Qualitative-Impact-of-Non-Medical-Switching_Report_Feb-2019.pdf (February 2019).
- Impact of Non-Medical Switching on Healthcare Costs: A Claims Database Analysis. Value in Health, Volume 18 Issue 3 (May 2015): PA252.
- Costs Associated with Non-Medical Switching from Originator to Biosimilar Etanercept in Patients with Rheumatoid Arthritis in the UK. Journal of Medical Economics, Volume 22 Issue 11 (November 2019): P1162-1170.